{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T15:27:55Z","timestamp":1767972475287,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,10,17]],"date-time":"2009-10-17T00:00:00Z","timestamp":1255737600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1007\/s10875-009-9335-3","type":"journal-article","created":{"date-parts":[[2009,10,16]],"date-time":"2009-10-16T11:30:33Z","timestamp":1255692633000},"page":"106-113","source":"Crossref","is-referenced-by-count":25,"title":["Long-Term Cerebrospinal Fluid and Blood Lymphocyte Dynamics After Rituximab for Pediatric Opsoclonus-Myoclonus"],"prefix":"10.1007","volume":"30","author":[{"given":"Michael R.","family":"Pranzatelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth D.","family":"Tate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna L.","family":"Travelstead","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry A.","family":"Colliver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,10,17]]},"reference":[{"key":"9335_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2008.07.019","volume":"204","author":"J-P St\u00fcben","year":"2008","unstructured":"St\u00fcben J-P. B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders. J Neuroimmunol. 2008;204:1\u201312.","journal-title":"J Neuroimmunol."},{"key":"9335_CR2","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/archneur.62.2.258","volume":"62","author":"NL Monson","year":"2005","unstructured":"Monson NL, Cravens PD, Frohman EM, Hawker K, Racke MK. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol. 2005;62:258\u201364.","journal-title":"Arch Neurol."},{"key":"9335_CR3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jneuroim.2006.06.029","volume":"180","author":"AH Cross","year":"2006","unstructured":"Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons J. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol. 2006;180:63\u201370.","journal-title":"J Neuroimmunol."},{"key":"9335_CR4","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/jnnp.74.4.485","volume":"74","author":"A Pestronk","year":"2003","unstructured":"Pestronk A, Florence J, Miller T, Choksi R, Al-Lozi MT, Levine TD. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry. 2003;74:485\u20139.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"9335_CR5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.clim.2006.08.009","volume":"122","author":"JH Anolik","year":"2007","unstructured":"Anolik JH, Friedberg JW, Zheng B, Barnard J, Owen T, Cushing E, et al. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol. 2007;122:139\u201345.","journal-title":"Clin Immunol."},{"key":"9335_CR6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s12016-007-8015-4","volume":"34","author":"JO Pers","year":"2008","unstructured":"Pers JO, Daridon C, Bendaoud B, Devauchelle V, Berthou C, Saraux A, et al. B-cell depletion and repopulation in autoimmune diseases. Clin Rev Allergy Immunol. 2008;34:50\u20135.","journal-title":"Clin Rev Allergy Immunol."},{"key":"9335_CR7","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/ard.2006.057885","volume":"66","author":"M Tokunaga","year":"2007","unstructured":"Tokunaga M, Saito K, Kawabata D, Imura Y, Fujii T, Nakayamada S, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66:470\u20135.","journal-title":"Ann Rheum Dis."},{"key":"9335_CR8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/1043454204272560","volume":"22","author":"ED Tate","year":"2005","unstructured":"Tate ED, Allison TJ, Pranzatelli MR, Verhulst SJ. Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome. J Pediatr Oncol Nurs. 2005;22:8\u201319.","journal-title":"J Pediatr Oncol Nurs."},{"issue":"suppl 11","key":"9335_CR9","first-page":"S113","volume":"62","author":"ED Tate","year":"2007","unstructured":"Tate ED, Pranzatelli MR, Harber JA, Travelstead AL, Verhulst SJ, Fenton GA, et al. Pharmacokinetic and time-course study of rituximab in pediatric opsoclonus-myoclonus syndrome. Ann Neurol. 2007;62(suppl 11):S113.","journal-title":"Ann Neurol."},{"key":"9335_CR10","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1542\/peds.2004-0845","volume":"115","author":"MR Pranzatelli","year":"2005","unstructured":"Pranzatelli MR, Tate ED, Travelstead AL, Longee D. Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus. Pediatrics. 2005;115:e115\u20139.","journal-title":"Pediatrics."},{"key":"9335_CR11","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/mds.20125","volume":"19","author":"MR Pranzatelli","year":"2004","unstructured":"Pranzatelli MR, Travelstead AL, Tate ED, Allison TJ, Verhulst SJ. CSF B cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity. Mov Disord. 2004;19:770\u20137.","journal-title":"Mov Disord."},{"key":"9335_CR12","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/01.mph.0000212991.64435.f0","volume":"28","author":"MR Pranzatelli","year":"2006","unstructured":"Pranzatelli MR, Tate ED, Travelstead AL, Barbosa J, Bergamini RA, Civitello L, et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol\/Oncol. 2006;28:585\u201393.","journal-title":"J Pediatr Hematol\/Oncol."},{"key":"9335_CR13","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1212\/WNL.62.9.1526","volume":"62","author":"MR Pranzatelli","year":"2004","unstructured":"Pranzatelli MR, Travelstead AL, Tate ED, Allison TJ, Moticka EJ, Franz DN, et al. B- and T-cell markers in opsoclonus-myoclonus syndrome: immunophenotyping of CSF lymphocytes. Neurology. 2004;62:1526\u201332.","journal-title":"Neurology."},{"key":"9335_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00002826-199619010-00001","volume":"19","author":"MR Pranzatelli","year":"1996","unstructured":"Pranzatelli MR. The immunopharmacology of the opsoclonus-myoclonus syndrome. Clin Neuropharmacol. 1996;19:1\u201347.","journal-title":"Clin Neuropharmacol."},{"key":"9335_CR15","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0022-3476(97)70200-2","volume":"130","author":"WM Comans-Bitter","year":"1997","unstructured":"Comans-Bitter WM, De Groot R, van den Beemd R, Neijens HJ, Hop WC, Groeneveld K, et al. Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations. J Pediatr. 1997;130:388\u201393.","journal-title":"J Pediatr."},{"key":"9335_CR16","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.2741\/2254","volume":"12","author":"I Sanz","year":"2007","unstructured":"Sanz I, Anolik JH, Looney RJ. B cell depletion therapy in autoimmune diseases. Front Biosci. 2007;12:2546\u201367.","journal-title":"Front Biosci."},{"key":"9335_CR17","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1600-0404.2007.00958.x","volume":"117","author":"HF Petereit","year":"2008","unstructured":"Petereit HF, Moeller-Hartmann W, Reske D, Rubbert A. Rituximab in a patient with multiple sclerosis\u2014effect on B cells, plasma cells and intrathecal IgG synthesis. Acta Neurol Scand. 2008;117:399\u2013403.","journal-title":"Acta Neurol Scand."},{"key":"9335_CR18","first-page":"1620","volume":"62","author":"O St\u00fcve","year":"2005","unstructured":"St\u00fcve O, Cepok S, Elias B, Saleh A, Hartung HP, Hemmer B, et al. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing\u2013remitting multiple sclerosis. Arch Neurol. 2005;62:1620\u20133.","journal-title":"Arch Neurol."},{"key":"9335_CR19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3233\/HAB-2004-13301","volume":"13","author":"RA Sidner","year":"2004","unstructured":"Sidner RA, Book BK, Agarwal A, Bearden CM, Vieira CA, Pescovitz MD. In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody. Hum Antib. 2004;13:55\u201362.","journal-title":"Hum Antib."},{"key":"9335_CR20","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.clim.2006.08.016","volume":"122","author":"T Vallerskog","year":"2007","unstructured":"Vallerskog T, Gunnarsson I, Widhe M, Risselada A, Klareskog L, van Vollenhoven R, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol. 2007;122:62\u201374.","journal-title":"Clin Immunol."},{"key":"9335_CR21","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1182\/blood-2002-11-3569","volume":"101","author":"NL Bernasconi","year":"2003","unstructured":"Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity. Upregulation of TLR9 by BCR triggering in na\u00efve B cells and constitutive expression in memory B cells. Blood. 2003;101:4500\u20134.","journal-title":"Blood."},{"key":"9335_CR22","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20430","volume":"50","author":"RJ Looney","year":"2004","unstructured":"Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50:2580\u20139.","journal-title":"Arthritis Rheum."},{"key":"9335_CR23","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1002\/art.22019","volume":"54","author":"P Roll","year":"2006","unstructured":"Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. 2006;54:2377\u201386.","journal-title":"Arthritis Rheum."},{"key":"9335_CR24","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1111\/j.1600-6143.2006.01497.x","volume":"6","author":"H Genberg","year":"2006","unstructured":"Genberg H, Hansson A, Wernerson A, Wennberg L, Tyd\u00e9n G. Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant. 2006;6:2418\u201328.","journal-title":"Am J Transplant."},{"key":"9335_CR25","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","volume":"54","author":"MJ Leandro","year":"2006","unstructured":"Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:613\u201320.","journal-title":"Arthritis Rheum."},{"key":"9335_CR26","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1182\/blood-2007-02-068999","volume":"110","author":"R Stasi","year":"2007","unstructured":"Stasi R, Del Poeta G, Stipa E, Evangelista ML, Trawinska MM, Cooper N, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood. 2007;110:2924\u201330.","journal-title":"Blood"},{"key":"9335_CR27","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1600-6143.2004.00502.x","volume":"4","author":"A Agarwal","year":"2004","unstructured":"Agarwal A, Vieira CA, Book BK, Sidner RA, Fineberg NS, Pescovitz MD. Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T cell responses. Am J Transplant. 2004;4:1357\u201360.","journal-title":"Am J Transplant."}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-009-9335-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10875-009-9335-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-009-9335-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T06:07:13Z","timestamp":1685167633000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10875-009-9335-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,17]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["9335"],"URL":"https:\/\/doi.org\/10.1007\/s10875-009-9335-3","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,17]]}}}